{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T21:00:28Z","timestamp":1795122028551,"version":"4.10.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Cardiol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00246-022-02983-0","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T12:02:55Z","timestamp":1660132975000},"page":"146-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Early Clinical Experience with Dapagliflozin in Children with Heart Failure"],"prefix":"10.1007","volume":"44","author":[{"given":"David M.","family":"Newland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuk M.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Friedland-Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humera","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariska S.","family":"Kemna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borah J.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"2983_CR1","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.healun.2014.06.002","volume":"33","author":"R Kirk","year":"2014","unstructured":"Kirk R, Dipchand AI, Rosenthal DN et al (2014) the international society for heart and lung transplantation guidelines for the management of pediatric heart failure: executive summary. J Heart Lung Transplant 33:888\u2013909. https:\/\/doi.org\/10.1016\/j.healun.2014.06.002","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"2983_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.21037\/cdt-20-358","volume":"11","author":"H Ahmed","year":"2021","unstructured":"Ahmed H, Vanderpluym C (2021) Medical management of pediatric heart failure. Cardiovasc Diagn Ther 11(1):323\u2013335. https:\/\/doi.org\/10.21037\/cdt-20-358","journal-title":"Cardiovasc Diagn Ther"},{"key":"2983_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jpeds.2016.06.003","volume":"177","author":"BS Moffett","year":"2016","unstructured":"Moffett BS, Humlicek TJ, Rossano JW, Price JF, Cabrera AG (2016) Readmissions for heart failure in children. J Pediatr 177:153-158.e3. https:\/\/doi.org\/10.1016\/j.jpeds.2016.06.003","journal-title":"J Pediatr"},{"key":"2983_CR4","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"TM Maddox","year":"2021","unstructured":"Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Patterson JH, Walsh MN, Wasserman A, Yancy CW, Youmans QR (2021) 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 77:772\u2013810. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.022","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2983_CR5","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/CIRCULATIONAHA.120.047077","volume":"142","author":"AM Jackson","year":"2020","unstructured":"Jackson AM, Dewan P, Anand IS et al (2020) Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF [published correction appears in Circulation. 2020 Nov 17;142(20):e369]. Circulation. 142(11):1040\u20131054. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.047077","journal-title":"Circulation."},{"issue":"2","key":"2983_CR6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2174\/1573403x12666151119165628","volume":"12","author":"A Riley","year":"2016","unstructured":"Riley A, Gebhard DJ, Akcan-Arikan A (2016) Acute kidney injury in pediatric heart failure. Curr Cardiol Rev 12(2):121\u2013131. https:\/\/doi.org\/10.2174\/1573403x12666151119165628","journal-title":"Curr Cardiol Rev"},{"issue":"17","key":"2983_CR7","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/eurjpc\/zwab173","volume":"28","author":"N Zhang","year":"2022","unstructured":"Zhang N, Wang Y, Tse G et al (2022) Effect of sodium-glucose cotransporter-2 inhibitors on cardiac remodelling: a systematic review and meta-analysis. Eur J Prev Cardiol 28(17):1961\u20131973. https:\/\/doi.org\/10.1093\/eurjpc\/zwab173","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"2983_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12933-020-01209-y","volume":"20","author":"YW Yu","year":"2021","unstructured":"Yu YW, Zhao XM, Wang YH et al (2021) Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Cardiovasc Diabetol 20(1):25. https:\/\/doi.org\/10.1186\/s12933-020-01209-y","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"2983_CR9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","volume":"322","author":"JL Januzzi Jr","year":"2019","unstructured":"Januzzi JL Jr, Prescott MF, Butler J et al (2019) Association of change in n-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 322(11):1085\u20131095. https:\/\/doi.org\/10.1001\/jama.2019.12821","journal-title":"JAMA"},{"issue":"1","key":"2983_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/eurheartj\/ehx564","volume":"39","author":"JGF Cleland","year":"2018","unstructured":"Cleland JGF, Bunting KV, Flather MD et al (2018) Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39(1):26\u201335. https:\/\/doi.org\/10.1093\/eurheartj\/ehx564","journal-title":"Eur Heart J"},{"issue":"9","key":"2983_CR11","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.amjcard.2010.06.052","volume":"106","author":"E Vizzardi","year":"2010","unstructured":"Vizzardi E, D\u2019Aloia A, Giubbini R et al (2010) Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol 106(9):1292\u20131296. https:\/\/doi.org\/10.1016\/j.amjcard.2010.06.052","journal-title":"Am J Cardiol"},{"issue":"16","key":"2983_CR12","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385(16):1451\u20131461. https:\/\/doi.org\/10.1056\/NEJMoa2107038","journal-title":"N Engl J Med"},{"key":"2983_CR13","doi-asserted-by":"publisher","first-page":"6657380","DOI":"10.1155\/2021\/6657380","volume":"2021","author":"RP Cai","year":"2021","unstructured":"Cai RP, Xu YL, Su Q (2021) Dapagliflozin in patients with chronic heart failure: a systematic review and meta-analysis. Cardiol Res Pract 2021:6657380. https:\/\/doi.org\/10.1155\/2021\/6657380","journal-title":"Cardiol Res Pract"},{"key":"2983_CR14","volume-title":"Package insert","author":"Entresto","year":"2021","unstructured":"Entresto (2021) Package insert. Novartis Pharmaceuticals Corporation"},{"issue":"21","key":"2983_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"}],"container-title":["Pediatric Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-022-02983-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00246-022-02983-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00246-022-02983-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T13:18:12Z","timestamp":1674134292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00246-022-02983-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["2983"],"URL":"https:\/\/doi.org\/10.1007\/s00246-022-02983-0","relation":{},"ISSN":["0172-0643","1432-1971"],"issn-type":[{"value":"0172-0643","type":"print"},{"value":"1432-1971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"20 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors listed in this manuscript have no conflicts of interest to disclose and have approved the final article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The need for informed consent was waived for this study of deidentified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}